新型冠状病毒肺炎诊疗的若干思考

doi:10.3969/j.issn.1006-7795.2020.03.002

摘要/Abstract

摘要： 作为一种新发的传染性极强的呼吸道疾病，新型冠状病毒肺炎（COVID-19，以下简称新冠肺炎）在全球范围内传播、蔓延。目前，该病已经造成了数以百万计的人感染、近30万人死亡，严重威胁着人类生命财产安全等众多方面。本文通过在临床治疗过程中对该疾病特点及疾病演变规律的总结，为新冠肺炎的诊治提供参考。

关键词: 新型冠状病毒肺炎, 诊断, 治疗, 思考

Abstract: As a newly emerged and highly infectious respiratory disease, the COVID-19 is spreading around the world. This disease has infected millions of people and many of them die in the end. It is a serious threat to the safety of human life and property.We provide references for diagnosis and treatment of the COVID-19 by summarizing the characteristics and evolutions of the disease in clinical treatment.

Key words: COVID-19, diagnosis, treatment, thoughts

中图分类号:

R563.1

刘景院, 郭贺冰, 李昂. 新型冠状病毒肺炎诊疗的若干思考[J]. 首都医科大学学报, 2020, 41(3): 328-335.

Liu Jingyuan, Guo Hebing, Li Ang. Some thoughts on diagnosis and treatment of the COVID-19[J]. Journal of Capital Medical University, 2020, 41(3): 328-335.

参考文献

[1] WHO. Coronavirus disease (COVID-19) pandemic[EB/OL]. (2020-5-12)[2020-5-20]. http://doi:10.3760/cma.j.issn.2096-1588.2020.10000036.
[2] 中国医师协会心血管内科医师分会.体外膜肺氧合在成人新型冠状病毒感染合并心血管急危重症患者中的使用专家共识[J/OL]. 中华心血管病杂志(网络版).(2020-3-17)[2020-5-20]. http://doi:10.3760/cma.j.issn.2096-1588.2020.10000036.
[3] 国家卫生健康委. 新型冠状病毒肺炎诊疗方案(试行第七版)[EB/OL].(2020-3-12)[2020-5-20].http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350a8ce964.pdf.
[4] Xiao F, Tang M, Zheng X, et al. Evidence for gastrointestinal infection of SARS-CoV-2[J]. Gastroenterology, 2020, 158(6):1831-1833.
[5] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223):497-506.
[6] Jin Y, Yang H, Ji W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19[J]. Viruses, 2020, 12(4):372.
[7] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. The Lancet Respirat Med, 2020, 8(4):420-422.
[8] Zhou P, Yang X, Wang X, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 579(7798):270-273.
[9] Zhen L, Ming W, Jiawei Y, et al. Caution on Kidney Dysfunctions of COVID-19 Patients[J/OL]. medRxiv Print. (2020-3-27)[2020-5-20]. https://doi.org/10.1101/2020.02.08.20021212.
[10] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223):497-506.
[11] Li X, Geng M, Peng Y, et al. Molecular immune pathogenesis and diagnosis of COVID-19[J]. J Pharm Anal, 2020, 10(2):102-108.
[12] 刘茜,王荣帅,屈国强,等. 新型冠状病毒肺炎死亡尸体系统解剖大体观察报告[J]. 临床指南汇编数据库, 2020,36(1):21-23.
[13] Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19[J]. Kidney Int, 2020(97):829-838.
[14] 夏黎明,黄璐,韩瑞,等. 新型冠状病毒肺炎不同临床分型间CT和临床表现的相关性研究[J]. 中华放射学杂志, 2020, 54(4):300-304.
[15] 贺永斌,刘国利,翟丽丽,等.新型冠状病毒肺炎临床分型及CT表现分析[J]. 中国实验诊断学, 2020, 24(4):603-605.
[16] Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses:from mechanisms to potential therapeutic tools[J/OL]. Virol Sin. (2020-3-3)[2020-5-20]. https://doi:10.1007/s12250-020-00207-4.
[17] Takada A,Kawaoka Y. Antibody-dependent enhancement of viral infection:molecular mechanisms and in vivo implications[J]. Rev Med Virol, 2003, 13(6):387-398.
[18] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019[J]. N Engl J Med, 2020, 382(8):727-733.
[19] Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China[J/OL]. Clin Infect Dis. (2020-3-12)[2020-5-20]. https://doi:10.1093/cid/ciaa248.
[20] Omrani A S, Saad M M, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection:a retrospective cohort study[J]. Lancet Infect Dis, 2014, 14(11):1090-1095.
[21] Falzarano D, de Wit E, Rasmussen A L, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques[J]. Nat Med, 2013, 10(19):1313-1317.
[22] Zumla A, Chan J F W, Azhar E I, et al. Coronaviruses-drug discovery and therapeutic options[J]. Nat Rev Drug Discovery, 2016, 15(5):327-347.
[23] Chu C M, Cheng V C, Hung I F, et al. Role of lopinavir/ritonavir in the treatment of SARS:initial virological and clinical findings[J]. Thorax, 2004, 59(3):252-256.
[24] Kim U J, Won E J, Kee S J, et al. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome[J]. Antivir Ther, 2016, 21(5):455-459.
[25] Hoehl S, Rabenau H, Berger A, et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China[J]. N Engl J Med, 2020, 382(13):1278-1280.
[26] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro[J]. Cell Res, 2020, 30(3):269-271.
[27] Robin E F, Jeffrey K A. Chloroquine and hydroxychloroquine in covid-19[J/OL]. BMJ. (2020-4-8)[2020-5-20]. https://doi:10.1136/bmj.m1432.
[28] Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia[J]. Aging Dis, 2020, 11(2):216-228.
[29] Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19[J]. Infect Dis, 2020, 80(6):607-613.
[30] Auyeung T W, Lee J S, Lai W K, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes:a retrospective cohort study[J]. J Infect, 2005, 51(2):98-102.
[31] Zhou Y, Qin Y, Lu Y, et al. Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia:protocol of a randomized controlled trial[J]. Chin Med J (Engl), 2020, 133(9):1080-1086.
[32] Zuccari S, Damiani E, Domizi R, et al. Changes in cytokines, haemodynamics and microcirculation in patients with sepsis/septic shock undergoing continuous renal replacement therapy and blood purification with cytosorb[J]. Blood Purif, 2020, 49(1-2):107-113.
[33] Ren J L, Zhang A H, Wang X J. Traditional Chinese medicine for COVID-19 treatment[J/OL]. Pharmacol Res. (2020-3-25)[2020-5-20]. https://doi:10.1016/j.phrs.2020.104768.
[34] Ding Y, Zeng L, Li R, et al. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function[J]. BMC Complement Altern Med, 2017, 17(1):130.
[35] Petersen E, Hui D, Hamer D H, et al. Li Wenliang, a face to the frontline healthcare worker. The first doctor to notify the emergence of the SARS-CoV-2, (COVID-19), outbreak[J]. Int J Infect Dis, 2020, 93:205-207.
[36] Chen G, Gao Y, Jiang Y, et al. Efficacy and Safety of Xuebijing Injection Combined WithUlinastatin as Adjunctive Therapy on Sepsis:A Systematic Review and Meta-Analysis[J]. Front Pharmacol, 2018, 9:743.
[37] Wang P, Song Y, Liu Z, et al. Xuebijing injection in the treatment of severe pneumonia:study protocol for a randomized controlled trial[J]. Trials, 2016, 17(1):142.
[38] 中华医学会呼吸病学分会,中国医师协会呼吸医师分会. 新型冠状病毒肺炎防治专家意见[J/OL]. 中华结核和呼吸杂志.(2020-4-5)[2020-5-20]. https://doi:10.3760/cma.j.cn112147-112147-20200321-00392.
[39] 中国研究型医院学会危重医学专业委员会.中国研究型医院学会危重医学专委会青年委员会. 重型和危重型新型冠状病毒肺炎诊断和治疗专家共识[J]. 中华危重病急救医学, 2020, 32(2):129-134.
[40] 王加芳,卢凡,周明星,等. 重型和危重型新型冠状病毒肺炎患者实施气管插管的临床分析[J]. 南方医科大学学报,2020,40(3):337-341.
[41] 余追,姚兰,姜洁,等. 危重型新型冠状病毒肺炎成功救治经验[J]. 中国中西医结合急救杂志, 2020, 27(2):200-203.
[42] 张伟,潘纯,宋青. 危重症新型冠状病毒肺炎肺损伤治疗过程中应关注的问题[J]. 解放军医学杂志, 2020, 45(3):236-240.
[43] 高健,樊国爱,李树波,等. 危重型新型冠状病毒肺炎患者俯卧位机械通气效果观察[J]. 中国煤炭工业医学杂志, 2020, 23(2):217-220.
[44] 李长城,余旻. 俯卧位通气治疗急性呼吸窘迫综合征患者疗效的Meta分析[J]. 海南医学,2020, 31(4):529-533.